Registration and follow-up of patients with aplastic anemia

Registration and follow-up of patients with aplastic anemia - Registration and follow-up of patients with aplastic anemia

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048337

Enrollment

800

Registered

2022-07-12

Start date

2022-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aplastic anemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who were diagnosed with aplastic anemia after September 1st, 2017 2) Patients who give written consent to participate in the study

Exclusion criteria

Exclusion criteria: 1) Patients who are ineligible for the study by researchers' judgement

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Severity by age and gender/ first-line treatment/ response rate of first-line treatment/ progression-free survival and relapse rate/ second-line and third-line treatment and their response rate/ complications (reactivation of CMV or EBV)/ frequency of refractory disease/ the rate and period of progression to paroxysmal nocturnal hemoglobinuria/ the rate and period of progression to myelodysplastic syndromes or acute myeloid leukemia/ emergence of chromosomal abnormalities after treatment/ prognostic factors for survival/ predictive factors for treatment response	—

Measure

Time frame

Severity by age and gender/ first-line treatment/ response rate of first-line treatment/ progression-free survival and relapse rate/ second-line and third-line treatment and their response rate/ complications (reactivation of CMV or EBV)/ frequency of refractory disease/ the rate and period of progression to paroxysmal nocturnal hemoglobinuria/ the rate and period of progression to myelodysplastic syndromes or acute myeloid leukemia/ emergence of chromosomal abnormalities after treatment/ prognostic factors for survival/ predictive factors for treatment response

—

Countries

Japan

Contacts

Public ContactFumi Nakamura

Dokkyo Medical University Department of Hematology and Oncology

funakamu@dokkyomed.ac.jp0282-86-1111

Outcome results